Drug intelligence / Profile preview

isomangiferin

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral, Topical, Intravenous, Intraperitoneal
01

Overview

Isomangiferin is a naturally occurring xanthone C-glycoside found in plants such as Mangifera indica (mango) and other species. It belongs to the class of organic compounds known as xanthones—polycyclic aromatic compounds containing a xanthene moiety conjugated to a ketone group at carbon 9[5][8][9]. Isomangiferin exhibits several biological activities including antiviral effects (notably against herpes simplex virus type I), antioxidant and radical-scavenging properties[3][4][10]. Mechanistically, it has been shown to inhibit viral replication within cells and functionally inhibit vascular endothelial growth factor receptor 2 (VEGFR-2), thereby suppressing angiogenesis and tumor growth in preclinical breast cancer models[3][7]. Its anti-cancer activity involves induction of caspase-dependent apoptosis and inhibition of VEGF-induced signaling pathways related to proliferation, migration, invasion, adhesion of cancer cells, and blood vessel formation[7].

Other names
9H-xanthen-9-one, 4-beta-D-glucopyranosyl-1,3,6,7-tetrahydroxy-
02

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on isomangiferin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on isomangiferin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call